Vitrification Versus Slow Freezing of Human Day 3 Embryos

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by University Hospital, Gasthuisberg.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University Hospital, Gasthuisberg
ClinicalTrials.gov Identifier:
NCT00710723
First received: January 4, 2008
Last updated: July 3, 2008
Last verified: January 2008
  Purpose

In assisted reproduction technology (ART), cryopreservation of embryos maximizes the potential of IVF cycles. Currently different cryopreservation methods are used, the conventional slow freezing method and vitrification. There is, therefore an immediate need to assess which cryopreservation technique is preferential in human IVF. In this prospective randomised study conventional slow freezing and vitrification, using the Hemi-straw carrier system, of human day 3 embryos were compared.


Condition Intervention
Cleavage Stage, Ovum
Procedure: vitrification

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Vitrification Versus Slow Freezing of Human Day 3 Embryos

Further study details as provided by University Hospital, Gasthuisberg:

Primary Outcome Measures:
  • Pregnancy rate [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • survival rate after thawing of embryos [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]

Enrollment: 901
Study Start Date: October 2005
Estimated Study Completion Date: December 2008
Arms Assigned Interventions
Experimental: 1
vitrification
Procedure: vitrification
Vitrification using Hemi-straw carrier system.
No Intervention: 2
Slow freezing

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 43 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Embryos of sufficient embryo quality: at least 6 cells on day 3 and less than 20 % fragmentation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00710723

Locations
Belgium
UZ Leuven
Leuven, Belgium, 3000
Sponsors and Collaborators
University Hospital, Gasthuisberg
Investigators
Principal Investigator: D'Hooghe Thomas, Prof. Dr. UZ Leuven
  More Information

No publications provided

Responsible Party: Prof. Dr. Thomas D'Hooghe, University Hospital, Gasthuisberg.
ClinicalTrials.gov Identifier: NCT00710723     History of Changes
Other Study ID Numbers: dwille1
Study First Received: January 4, 2008
Last Updated: July 3, 2008
Health Authority: Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment

ClinicalTrials.gov processed this record on September 22, 2014